Medical Equipment

Liposomal Drug Delivery Devices Market Revenue Expected to Reach $9.49 Billion by 2030 with 12.1% CAGR

March 13, 2026March 16, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Liposomal Drug Delivery Devices Market From 2026 To 2030?

The liposomal drug delivery devices market has experienced rapid expansion in recent years. This market is projected to expand from $5.34 billion in 2025 to $6.01 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 12.4%. Historically, this growth has been driven by factors such as advancements in nanotechnology-based drug delivery, increasing cancer prevalence, the expansion of injectable drug formulations, the rising use of liposomal antifungal therapies, and growing pharmaceutical research investments.

The liposomal drug delivery devices market is expected to experience substantial growth in the upcoming years. It is projected to expand to $9.49 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.1%. The expansion in this forecast period can be attributed to the increasing need for targeted cancer treatments, the broadening scope of personalized medicine approaches, the rising adoption of advanced drug delivery platforms, growing investments in biologics and vaccines, and an increased focus on reducing drug toxicity. Significant trends for the forecast period include the increasing incorporation of targeted drug delivery systems, the rising usage of pegylated liposomal formulations, their expanding application in oncology therapies, the proliferation of liposomal vaccines and antifungals, and an enhanced emphasis on controlled drug release.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3349&type=smp

Which Growth Drivers Are Contributing To The Progress Of The Liposomal Drug Delivery Devices Market?

The global rise in cancer cases is anticipated to propel the growth of the liposomal drug delivery devices market in the future. Cancer encompasses a broad spectrum of diseases characterized by the uncontrolled proliferation and spread of abnormal cells, with its increasing occurrence attributed to the combined effects of population aging, environmental risk factors, and lifestyle changes. As the prevalence of cancer expands, a stronger demand emerges for advanced, targeted therapies such as liposomal formulations, which can enhance drug delivery, reduce systemic toxicity, and improve treatment efficacy. For example, the World Health Organization, a Switzerland-based intergovernmental organization, indicated in February 2024 that approximately 20 million new cancer cases occurred in 2022, with projections showing an increase to 35 million by 2050, signifying a 77% rise. Therefore, the escalating global burden of cancer is a primary driver for the expansion of the liposomal drug delivery devices market.

Which Segments Are Included In The Analysis Of The Liposomal Drug Delivery Devices Market?

The liposomal drug delivery devices market covered in this report is segmented –

1) By Type: Liposomal Doxorubicin, Liposomal Paclitaxel, Liposomal Amphotericin B, Other Types

2) By Application: Fungal Diseases, Cancer Therapy, Pain Management, Viral Vaccines, Photodynamic Therapy

3) By End User: Hospitals, Diagnostic Centers, Ambulatory Surgery Centers/Clinics, Other End Users

Subsegments:

1) By Liposomal Doxorubicin: Conventional Liposomal Doxorubicin, PEGylated Liposomal Doxorubicin

2) By Liposomal Paclitaxel: Conventional Liposomal Paclitaxel, PEGylated Liposomal Paclitaxel

3) By Liposomal Amphotericin B: Conventional Liposomal Amphotericin B, PEGylated Liposomal Amphotericin B

4) By Other Types: Liposomal Irinotecan, Liposomal Vincristine, Liposomal Cytarabine

Which Trends Are Impacting The Growth Of The Liposomal Drug Delivery Devices Market?

Key companies operating in the liposomal drug delivery market are introducing advanced products, such as hydrochloride liposome injections, to gain a market advantage. Researchers have been actively developing liposomal nanostructures that can enhance patient compliance by enabling less frequent dosing while maintaining their effectiveness. For instance, in August 2024, Lupin Ltd., an India-based pharmaceutical firm, launched Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL). The Doxorubicin Hydrochloride Liposome Injection achieved estimated annual sales of approximately USD 40.9 million in the U.S. market as of June 2024. This strategically positions Lupin within the oncology segment, expanding its product offerings to include this vital cancer treatment option. Lupin’s commitment to enhancing patient health outcomes is clear through this introduction, as it aims to provide effective treatment alternatives in a competitive pharmaceutical environment.

Which Key Industry Participants Are Active In The Liposomal Drug Delivery Devices Market?

Major companies operating in the liposomal drug delivery devices market are Pfizer Inc., Johnson & Johnson Services Inc., Merck & Co. Inc., Novartis AG, Gilead Sciences Inc., Ipsen SA, Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co. Ltd., Nanomerics Ltd., Luye Pharma Group Ltd., Leadiant Biosciences Inc., Pacira Biosciences Inc., Nippon Kayaku Co. Ltd., Celsion Corporation, Acrotech Biopharma Inc., Aphios Pharma LLC, CytImmune Sciences Inc., NanoSphere Health Sciences Inc., Cel-Sci Corporation, Lipoid GmbH, Liposome Company Inc., Liposome Research Days Corporation, Taiwan Liposome Company

Read the full liposomal drug delivery devices market report here:

https://www.thebusinessresearchcompany.com/report/liposomal-drug-delivery-devices-global-market-report

What Are The Leading Geographic Regions In The Liposomal Drug Delivery Devices Market?

North America was the largest region in the liposomal drug delivery devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liposomal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Liposomal Drug Delivery Devices Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=3349&type=smp

Browse Through More Reports Similar to the Global Liposomal Drug Delivery Devices Market 2026, By The Business Research Company

Liposuction Surgery Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/liposuction-surgery-devices-global-market-report

Pharmaceutical Drug Delivery Market Report 2026

https://www.thebusinessresearchcompany.com/report/pharmaceutical-drug-delivery-global-market-report

Liposomal Doxorubicin Market Report 2026

https://www.thebusinessresearchcompany.com/report/liposomal-doxorubicin-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795